Xlife Sciences AG (SWX:XLS)
Switzerland · Delayed Price · Currency is CHF 24.70
-0.50 (-1.98%)
At close: Jun 22, 2026
Xlife Sciences AG Revenue
In the year 2025, Xlife Sciences AG had annual revenue of 275.31K CHF, down -67.02%. Xlife Sciences AG had revenue of -79.01K in the half year ending December 31, 2025.
Revenue
275.31K
Revenue Growth
-67.02%
P/S Ratio
511.59
Revenue / Employee
13.77K
Employees
20
Market Cap
140.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 275.31K | -559.57K | -67.02% |
| Dec 31, 2024 | 834.88K | -153.56K | -15.54% |
| Dec 31, 2023 | 988.44K | -39.54K | -3.85% |
| Dec 31, 2022 | 1.03M | 221.91K | 27.53% |
| Dec 31, 2021 | 806.07K | 409.26K | 103.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 695.07M |
| Basilea Pharmaceutica AG | 232.38M |
| Idorsia | 219.10M |
| Santhera Pharmaceuticals Holding AG | 77.19M |
| Newron Pharmaceuticals | 17.81M |
| BioVersys AG | 3.18M |
| Molecular Partners AG | 681.00K |
| MindMaze Therapeutics Holding | 642.00K |